McDonough named CEO at T2 Biosystems

January 7, 2008 — T2 Biosystems Inc., which is developing portable medical diagnostic products that combine nanotechnology with miniaturized magnetic resonance imaging (MRI), has appointed John McDonough as chief executive officer. McDonough will also serve as a member of the company’s board of directors.

Most recently, McDonough served as President of Cytyc Development Corp., where he was responsible for corporate strategy, acquisitions and venture investments. During his four-year tenure at the medical diagnostic and devices company, Cytyc grew — primarily through acquisitions — from a single product company with annual revenues of $300 million to a multiple product company with revenues of $750 million. In 2007, Cytyc was acquired by Hologic, Inc. for $6.3 billion. Prior to his tenure at Cytyc, McDonough served as CEO at a number of technology companies, including SoundBite Communications, Workgroup Technology Corporation and Easel Corporation.

“T2 Biosystems’ novel technology has the potential to revolutionize medical diagnostics and dramatically improve patient care by enabling immediate, accurate testing for almost any health condition, in nearly any setting,” said McDonough. He aims to lead the company in producing a prototype instrument; and identifying and progressing multiple diagnostic tests to the preclinical stage of development.


Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.